Literature DB >> 11091153

Public health paradoxes and the epidemiological impact of an HPV vaccine.

G P Garnett1, H C Waddell.   

Abstract

BACKGROUND: our understanding of human papilloma virus (HPV) and cervical cancer has improved dramatically, with a vaccine against the viral infection being a real possibility in the near future. AIMS: the goal of an HPV vaccine would be to reduce the prevalence of infection and hence the risk of cervical abnormalities. However, questions arise as to how this would interact with an existing intervention, screening, which reduces the progress of cervical abnormalities to serious disease. Furthermore, will a vaccine against one genotype influence the other types within a population and will the patterns of infection and disease remain the same if the vaccine alters the timing and type of HPVs experienced within a population? What would a vaccine that only worked in one sex achieve and how widespread would the use of such a vaccine have to be?
CONCLUSION: the above-given questions can be addressed within a theoretical framework that describes the transmission dynamics of human papilloma virus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091153     DOI: 10.1016/s1386-6532(00)00129-3

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  11 in total

Review 1.  How will HPV vaccines affect cervical cancer?

Authors:  Richard Roden; T-C Wu
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 2.  Vaccines for cervical cancer.

Authors:  C M Lowndes
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

3.  Prevalence and type distribution of human papillomavirus infection in women from North Sardinia, Italy.

Authors:  Andrea Piana; Giovanni Sotgiu; Paolo Castiglia; Stefania Pischedda; Clementina Cocuzza; Giampiero Capobianco; Vincenzo Marras; Salvatore Dessole; Elena Muresu
Journal:  BMC Public Health       Date:  2011-10-11       Impact factor: 3.295

Review 4.  Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries.

Authors:  Kari Natunen; Johannes Lehtinen; Proscovia Namujju; John Sellors; Matti Lehtinen
Journal:  Infect Dis Obstet Gynecol       Date:  2011-07-19

5.  Evaluating human papillomavirus vaccination programs.

Authors:  Al V Taira; Christopher P Neukermans; Gillian D Sanders
Journal:  Emerg Infect Dis       Date:  2004-11       Impact factor: 6.883

6.  Mathematical model of HPV provides insight into impacts of risk factors and vaccine.

Authors:  Jane J Kim
Journal:  PLoS Med       Date:  2006-04-04       Impact factor: 11.069

7.  Knowledge of cervical cancer and HPV vaccine in Bangladeshi women: a population based, cross-sectional study.

Authors:  Jessica Yasmine Islam; Fatema Khatun; Anadil Alam; Farhana Sultana; Afsana Bhuiyan; Nazmul Alam; Laura Reichenbach; Lena Marions; Mustafizur Rahman; Quamrun Nahar
Journal:  BMC Womens Health       Date:  2018-01-11       Impact factor: 2.809

8.  Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study.

Authors:  Sara E White; Steven A Harvey; Graciela Meza; Alejandro Llanos; Mitchel Guzman; Dionicia Gamboa; Joseph M Vinetz
Journal:  Malar J       Date:  2018-04-27       Impact factor: 2.979

9.  High HPV-51 prevalence in invasive cervical cancers: results of a pre-immunization survey in North Sardinia, Italy.

Authors:  Andrea Piana; Giovanni Sotgiu; Clementina Cocuzza; Rosario Musumeci; Vincenzo Marras; Stefania Pischedda; Silvia Deidda; Elena Muresu; Paolo Castiglia
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  The Digital Distribution of Public Health News Surrounding the Human Papillomavirus Vaccination: A Longitudinal Infodemiology Study.

Authors:  L Meghan Mahoney; Tang Tang; Kai Ji; Jessica Ulrich-Schad
Journal:  JMIR Public Health Surveill       Date:  2015-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.